Applying proteomics to the diagnosis and treatment of ALS and related diseases

Document Type

Article

Abstract

Protein-based biomarkers for amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs) have many potential clinical utilities, including diagnostic, prognostic, and drug development indications. During the past decade a number of potential protein biomarkers have been proposed for MNDs. Further verification studies, followed by large validation and qualification studies, are required to advance these initial discoveries toward clinical use. Study of additional patient populations, including disease mimics, is required during the validation phase of biomarker development. Important regulatory issues are discussed that will affect the timing and strategy for biomarker assay development in ALS and other MNDs. The continued development of protein biomarkers for MNDs requires extensive collaboration between academic clinicians and scientists in conjunction with the biotechnology and pharmaceutical industries. © 2009 Wiley Periodicals, Inc.

Keywords

Biomarkers, Motor neuron disease, Proteomics

Publication Date

11-1-2009

Publication Title

Muscle and Nerve

ISSN

0148639X

E-ISSN

10974598

Volume

40

Issue

5

First Page

753

Last Page

762

PubMed ID

19670321

Digital Object Identifier (DOI)

10.1002/mus.21488

This document is currently not available here.

Share

COinS